Lead-in dose optimization to mitigate cytokine release syndrome in AML and MDS patients treated with flotetuzumab, a CD123 X CD3 dart® molecule for T-cell redirected therapy

This article has no abstract
Epistemonikos ID: 993e1387054d091d0b06793ace7d81a50b64d705
First added on: Feb 08, 2025